FAD 20 crediti ECM per Oculisti

Official language: Italian
Simultaneous translation is provided
FAD 20 crediti
ECM per Oculisti
Ai partecipanti a
Retina in Progress: 65,00 €
(IVA inclusa)
Director: Alfredo PECE
Chairmen: Rosario BRANCATO, Ugo MENCHINI
International speakers:
BRESSLER N. (Baltimore)
BRESSLER S. (Baltimore)
BRUCKER A. (Philadelphia)
COSCAS. G (Paris)
SINGERMAN L. (Cleveland)
SOUBRANE G. (Paris)
YANNUZZI L. (New York)
WOLFENSBERGER T. (Lausanne)
SCIENTIFIC PROGRAMME: SATELLITE MEETINGS
Thursday, June 11th
RETINA IN GOAL…
BY GOAL (9.00 -11.00)
Director: T. Avitabile
Scientific Director: A. D’Amico
Speakers and Moderators: C. Alovisi, A. Basile, F. Dimastrogiovanni, D. Dolcino, V. Isola, R. Lattanzio, G.
Mandelli, P. Marino, C. Massironi, D. Mazzacane, E. Mengoni, A. Piatti, S. Reposi, F. Ronconi, F. Veneziano,
S. Vergani, C. Villani
1ST SESSION:
Chairmen: T. Avitabile, F. Ronconi
Moderator: S. Vergani
9.00
• Globalized epidemiology in retinal diseases - F. Dimastrogiovanni
9.10
• Macular edema after cataract surgery. News - S. Reposi
9.20
• Utility of photocoagulation therapy in diabetic maculopathy, present and future - R. Lattanzio
9.30
• News in glaucoma: a test for the evaluation of the pathological risk - P. Marino
9.40
DISCUSSION: Moderators: D. Mazzacane, C. Massironi, E. Mengoni
2ND SESSION:
Chairmen: C. M. Villani, D. Dolcino
Moderator: A. D’amico
10.00
• New diagnostic instruments for macular diseases- C. Alovisi
10.07
• Central serous chorioretinopathy in G.O.A.L. - G. Mandelli
10.14
• Intravitreal steroid therapy. News - A. Piatti
10.21
• Digital mobile imaging - V. Isola
10.30
• Low dose medicine - A. Basile
10.37
DISCUSSION: Moderators - D. Mazzacane, F. Veneziano
CONCLUSIONS: A. D’amico
LOW VISION IN MACULOPATHY:
LOW TECH MANAGEMENT IN A RETINA OFFICE
BY FONDAZIONE RETINA 3000 (09.00 - 11.00)
Scientific Directors: G. Giacomelli, G.Sato
Speakers and Moderators: M. Broggini, A. Grunberger, M. Schmid, G. Volpe
9.00
9.20
9.40
10.00
10.20
10.40
• “Low tech” placement in Low Vision patients with maculopathy - A. Grunberger
• “Low tech” correction in the near low vision - M. Broggini
• “Low tech” correction in far low vision - M. Schmid
• “Low tech” correction of low contrast sensitivity and in dazzling - G. Giacomelli
• “Low tech” minimum equipment in low vision - R. Volpe
DISCUSSION
3
MULTIMODALITY IMAGING
BY HEIDELBERG (9.00 - 11.00)
Scientific Director: F. Bottoni
Speakers and Moderators: M. Cereda, M. Cozzi, A. Giani, A. Invernizzi, G. Staurenghi
9.00
9.20
9.40
10.00
10.20
10.40
• Multicolor - M. Cozzi
• Wide-field imaging - M. Cereda
• Multi-imaging in inflammatory diseases - A. Invernizzi
• Multi-imaging in neoplastic diseases - A. Invernizzi
• Multi-imaging in AMD - A. Giani
• Angio-OCT - G. Staurenghi
DISCUSSION
ANGIO OCT: PRACTICAL APPLICATIONS WITH ANGIO VUE
BY ALFAINSTRUMENT AND OPTOVUE (10.30 - 11.30)
Scientific Director: Prof. B. Lumbroso
Speakers and Moderators: L. Di Antonio, B. Lumbroso, M. Rispoli, MC. Savastano
10.30
10.35
10.50
11.00
11.15
• Angio OCT: When, How and Why - B. Lumbroso
• Angio OCT and Fluorescein Angiography. Comparison and confrontation - L. Di Antonio
• Angio OCT techniques - MC. Savastano
• Retinal vascularization in normal retina and in vascular diseases - MC. Savastano
• CNV features and post treatment evolution - B. Lumbroso
DISCUSSION
DIABETIC MACULAR EDEMA:
PERSPECTIVES AND NEW THERAPEUTICAL APPROACHES
BY NOVARTIS (11.30 - 13.00)
Scientific Director: F. Bandello
Speakers and Moderators: M. Nicolò, F. Ricci, F. Viola
11.30
12.00
12.30
• Why treat early? Evidence from recent clinical trials - M. Nicolò
• Ranibizumab: freedom to extend - F. Viola
• Long term effects: prevention of RD worsening in DME patients - F. Ricci
DISCUSSION
IT IS TIME TO EXCHANGE EXPERTISE AND EXPERIENCE
BY BAYER (11.30 - 13.00)
Scientific Directors: P. Lanzetta, S. Rizzo
Speakers and Moderators: S. De Falco, F. Ghanchi, A. Russo, S. Vujosevic
11.30
11.45
12.00
12.15
• New players beyond VEGF - S. De Falco
• Exchange points of VIEW: international experience - F. Ghanchi
• Breaking news in DME - S. Vujosevic
• Long term experience with Aflibercept - A. Russo
DISCUSSION
4
POSTERIOR SEGMENT INFLAMMATORY DISEASES:
FROM THEORY TO CLINICAL EVIDENCE
BY THEA (18.00 - 19.15)
Scientific Directors: U. Menchini, G. Virgili
Speakers and Moderators: P. Allegri, S. Altimari, A. Minnella, F. Russo
18.00
18.20
18.30
18.40
18.50
• New options for posterior segment inflammatory diseases management - A. Minnella
• Treatment of inflammatory macular edema, a medical need already satisfied?- P. Allegri
• Diabetic macular edema, an alternative option to the wait and see strategy - F. Russo
• Macular edema post-cataract prevention, new opportunities over topical therapy
S. Altimari
DISCUSSION
Friday, June 12th
RETINA NIGHT
BY ALCON (18.00 - 19.15)
Moderator: S. Rizzo
Faculty: P. Arpa, F. Boscia, F. Bottoni, C. Mariotti, M. Romano
Learning objectives:
• Understanding the burden of disease of vitreomacular traction (VMT) and macular hole
(understanding patient impact of metamorphopsia and new IVTS classification)
• Real VMT epidemiology: the ideal pathway to increase patients enrollment, Careggi Hospital experience
• Understanding the importance of proper patient selection for Ocriplasmin / Vitrectomy (risk of surgery)
Early treatment vs. delayed treatment
When vitrectomy should be considered the first choice (ERM, high myopia, etc.)
Vitrectomy post Ocriplasmin injection (No VMT release, MH opening or MH enlargement)
• Case series and Italian real world data (first 100 patient injected) and key findings after the first
injections
Does the IVI technique influence the result?
• Ocriplasmin safety profile - Manage patient expectation pre-post injection
• What concerns do you have with the use of Ocriplasmin?
- Cost?
- Adverse events?
- Efficacy?
- Not easy to manage?
5